These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15262024)

  • 1. The role of coronary endothelial function testing in patients suspected for angina pectoris.
    Monnink SH; Tio RA; van Boven AJ; van Gilst WH; van Veldhuisen DJ
    Int J Cardiol; 2004 Aug; 96(2):123-9. PubMed ID: 15262024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute effects of ACE inhibition on coronary endothelial dysfunction.
    Nickenig G; Stäblein A; Wassmann S; Wyen C; Müller C; Böhm M
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):361-4. PubMed ID: 11967824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for ACE inhibition as an anti-ischaemic therapy.
    Pepine CJ
    Eur Heart J; 1998 Jul; 19 Suppl G():G34-40. PubMed ID: 9717054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction.
    Obata JE; Kitta Y; Takano H; Kodama Y; Nakamura T; Mende A; Kawabata K; Saitoh Y; Fujioka D; Kobayashi T; Yano T; Kugiyama K
    J Am Coll Cardiol; 2007 Oct; 50(14):1305-9. PubMed ID: 17903627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study.
    Stone PH; Lloyd-Jones DM; Kinlay S; Frei B; Carlson W; Rubenstein J; Andrews TC; Johnstone M; Sopko G; Cole H; Orav J; Selwyn AP; Creager MA;
    Circulation; 2005 Apr; 111(14):1747-55. PubMed ID: 15809368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term prognostic value of endothelial dysfunction in patients with chest pain and angiographically normal coronary arteries.
    Sánchez-Recalde A; Galeote G; Moreno R; Dobarro D; Gómez-Rubín MC; Calvo L; Sobrino N; Martin-Reyes R; Jiménez-Valero S; Sobrino JA; López-Sendón JL
    Rev Port Cardiol; 2009; 28(7-8):785-91. PubMed ID: 19894657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease.
    van der Harst P; Wagenaar LJ; Buikema H; Voors AA; Plokker HW; Morshuis WJ; Six AJ; Boonstra PW; Nickenig G; Wassmann S; van Veldhuisen DJ; van Gilst WH
    Am J Cardiol; 2005 Nov; 96(10):1361-4. PubMed ID: 16275178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
    Shah NC; Pringle S; Struthers A
    J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):20-30. PubMed ID: 17083070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of endothelial dysfunction in the pathogenesis and in clinical practice of atherosclerosis. Current evidences].
    Patti G; Melfi R; Di Sciascio G
    Recenti Prog Med; 2005 Oct; 96(10):499-507. PubMed ID: 16491775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of paraoxonase polymorphism (Q192R) on endothelial function in intact coronary circulation.
    Yamane T; Matsumoto T; Nakae I; Takashima H; Tarutani Y; Tamaki S; Horie M
    Hypertens Res; 2006 Jun; 29(6):417-22. PubMed ID: 16940704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial perfusion reserve in cardiovascular magnetic resonance: Correlation to coronary microvascular dysfunction.
    Wöhrle J; Nusser T; Merkle N; Kestler HA; Grebe OC; Marx N; Höher M; Kochs M; Hombach V
    J Cardiovasc Magn Reson; 2006; 8(6):781-7. PubMed ID: 17060099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.
    Mancini GB; Henry GC; Macaya C; O'Neill BJ; Pucillo AL; Carere RG; Wargovich TJ; Mudra H; Lüscher TF; Klibaner MI; Haber HE; Uprichard AC; Pepine CJ; Pitt B
    Circulation; 1996 Aug; 94(3):258-65. PubMed ID: 8759064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of use of cardiovascular drugs in 499 patients with suspected coronary artery disease at time of hospitalization for coronary angiography and in 357 patients with obstructive coronary artery disease documented by coronary angiography.
    Mazar M; Schair B; Aronow WS; Khalique O; Lehrman SG
    Am J Ther; 2008; 15(5):458-60. PubMed ID: 18806522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease.
    Zhao SP; Liu L; Cheng YC; Shishehbor MH; Liu MH; Peng DQ; Li YL
    Circulation; 2004 Aug; 110(8):915-20. PubMed ID: 15313947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.